Chromatin remodeling is known to be a major regulator of cancer gene expression programs, therefore knowledge of BRG1 involvement and targeted strategies developed in brain cancer are likely to be widely applicable to a variety of other cancer types where BRG1 has a clear role in tumourigenesis such as lung, ovarian and prostate cancer. Here, SMARCA4 is linked to prostate carcinoma.